Data / Drug companies / Ingenus Pharmaceuticals, LLC
Ingenus Pharmaceuticals, LLC: 141 products in the FDA NDC directory, labeler code 50742
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Ingenus Pharmaceuticals, LLC (labeler code 50742) lists 141 products in the FDA National Drug Code Directory, covering 58 finished drugs by generic name. By type: 137 prescription drugs, 4 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 16, 2026.
The request: Watch Ingenus Pharmaceuticals, LLC (FDA labeler code 50742): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 50742
- Products in commercial distribution
- 141
- Packages
- 234
- Finished drugs by generic name
- 58
- Prescription products
- 137
- Over the counter products
- 4
- Controlled substance products
- Schedule II 8, Schedule III 9, Schedule IV 6
- Flagged as original packager
- 139 of 139 products that carry the flag
- Started marketing in the last 12 months
- 4
- Products with a marketing end date set
- 1
- Earliest marketing start
- September 23, 2015
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 128 | 90.8% |
| New drug applications (NDA) | 7 | 5% |
| Authorized generics (NDA) | 3 | 2.1% |
| Other unapproved drugs | 3 | 2.1% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 137 | 97.2% |
| Over the counter drugs | 4 | 2.8% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 31 | 22% |
| Tablet, extended release | 31 | 22% |
| Patch, extended release | 14 | 9.9% |
| Tablet, film coated | 13 | 9.2% |
| Capsule, extended release | 10 | 7.1% |
| Patch | 9 | 6.4% |
| Capsule | 8 | 5.7% |
| Solution | 5 | 3.5% |
| Film | 4 | 2.8% |
| Solution/ drops | 4 | 2.8% |
| Tablet, orally disintegrating | 3 | 2.1% |
| Tablet, film coated, extended release | 3 | 2.1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Progesterone | 50742-359 | Insert | Generic drugs (ANDA) | October 16, 2026 |
| Nicotine Transdermal System | 50742-670 | Patch | Generic drugs (ANDA) | May 19, 2026 |
| Nicotine Transdermal System | 50742-669 | Patch | Generic drugs (ANDA) | May 19, 2026 |
| Nicotine Transdermal System | 50742-668 | Patch | Generic drugs (ANDA) | May 19, 2026 |
| Estrogens, conjugated | 50742-391 | Tablet, film coated | Generic drugs (ANDA) | October 16, 2025 |
| Estrogens, conjugated | 50742-390 | Tablet, film coated | Generic drugs (ANDA) | October 16, 2025 |
| Estrogens, conjugated | 50742-389 | Tablet, film coated | Generic drugs (ANDA) | October 16, 2025 |
| Estrogens, conjugated | 50742-388 | Tablet, film coated | Generic drugs (ANDA) | October 16, 2025 |
| Estrogens, conjugated | 50742-387 | Tablet, film coated | Generic drugs (ANDA) | October 16, 2025 |
| Prednisolone sodium phosphate ODT | 50742-385 | Tablet, orally disintegrating | Authorized generics (NDA) | September 15, 2025 |
| Prednisolone sodium phosphate ODT | 50742-384 | Tablet, orally disintegrating | Authorized generics (NDA) | September 15, 2025 |
| Prednisolone sodium phosphate ODT | 50742-383 | Tablet, orally disintegrating | Authorized generics (NDA) | September 15, 2025 |
| Dehydrated Alcohol | 50742-539 | Injection, solution | Generic drugs (ANDA) | July 9, 2025 |
| Diltiazem Hydrochloride | 50742-566 | Capsule, extended release | Generic drugs (ANDA) | July 3, 2025 |
| Diltiazem Hydrochloride | 50742-565 | Capsule, extended release | Generic drugs (ANDA) | July 3, 2025 |
| Diltiazem Hydrochloride | 50742-564 | Capsule, extended release | Generic drugs (ANDA) | July 3, 2025 |
| Formoterol Fumarate | 50742-394 | Solution | Generic drugs (ANDA) | June 5, 2025 |
| Oxcarbazepine | 50742-613 | Tablet, extended release | Generic drugs (ANDA) | June 1, 2025 |
| Oxcarbazepine | 50742-612 | Tablet, extended release | Generic drugs (ANDA) | June 1, 2025 |
| Oxcarbazepine | 50742-611 | Tablet, extended release | Generic drugs (ANDA) | June 1, 2025 |
| Hemiclor | 50742-285 | Tablet | New drug applications (NDA) | March 17, 2025 |
| Arformoterol Tartrate | 50742-395 | Solution | Generic drugs (ANDA) | March 1, 2025 |
| Fentanyl | 50742-555 | Patch, extended release | Generic drugs (ANDA) | February 11, 2025 |
| Fentanyl | 50742-553 | Patch, extended release | Generic drugs (ANDA) | February 10, 2025 |
| Fentanyl | 50742-551 | Patch, extended release | Generic drugs (ANDA) | February 5, 2025 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.